The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors
Single-arm, Open, Multi-center Phase I/Phase II Clinical Study to Assess the Safety, Tolerability, Pharmacokinetic and Effectiveness of VC004
Sponsor: Jiangsu vcare pharmaceutical technology co., LTD
Listed as NCT04614740, this PHASE1/PHASE2 trial focuses on Locally Advanced Solid Tumor and Metastatic Solid Tumor and remains ongoing. Sponsored by Jiangsu vcare pharmaceutical technology co., LTD, it has been updated 8 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Nov 2024 — Present [monthly]
Unknown PHASE1/PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Jan 2023 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Dec 2021 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Nov 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu vcare pharmaceutical technology co., LTD
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changsha, China , Chongqing, China , Fuzhou, China , Guangzhou, China , Haikou, China , Hangzhou, China , Harbin, China , Hefei, China , Jinan, China and 11 more locations